For those who suffer from irritable bowel syndrome with diarrhea, or IBS-D, the trouble is two-fold. Physically, they endure severe abdominal pain and possible nausea on a regular basis, as well as excessive amounts of gas and sudden urges to reach the nearest bathroom. But they also face potential embarrassment over their condition and can suffer anxiety and loss of appetite. These social aspects can have dramatic impacts on their quality ...
IBS-D Drug Could Threaten Patient Safety after Single Day’s Use
Posted October 12, 2017 in Drug and Medical Device Lawsuits | Product News and Recalls
Minimal Doses of Viberzi Could Be Deadly
Posted April 26, 2017 in Product News and Recalls
The FDA has issued a safety communication recommending that certain patients stop taking Allergan’s Viberzi, and for healthcare professionals to stop prescribing it to certain populations immediately.
Viberzi is supposed to help those with irritable bowel syndrome with diarrhea, or IBS-D, by decreasing bowel contractions, easing pain, and improving stool consistency.
Viberzi poses the most risk to individuals without a gallbladder. The FDA has received at least 120 ...
continue reading...IBS-D Drug Could Kill Those Without Gallbladder
Posted March 28, 2017 in Drug and Medical Device Lawsuits | Product News and Recalls
May 27, 2015 was a busy day at the FDA and a good day for two competing pharmaceutical companies. Allergan’s Viberzi, as well as Valeant’s Xifaxan medications were both approved by the agency to treat IBS-D, or irritable bowel syndrome with diarrhea.
Patients suffering from irritable bowel syndrome must contend with frequent agonizing bouts of lower stomach distress. The pain can be intense and is amplified by ...
continue reading...
